Abstracts tagged "steroids and systemic lupus erythematosus (SLE)"

Abstract Number: 2673 • 2018 ACR/ARHP Annual Meeting
Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
Matteo Piga¹, Gian Domenico Sebastiani², Imma Prevete³, Florenzo Iannone⁴, Laura Coladonato⁵, Marcello Govoni⁶, Alessandra Bortoluzzi⁷, Marta Mosca⁸, Chiara Tani⁸, Andrea Doria⁹, Luca Iaccarino¹⁰, Angela Tincani¹¹, Micaela Fredi¹², Fabrizio Conti¹³, Francesca Spinelli¹⁴, Mauro Galeazzi¹⁵, Francesca Bellisai¹⁶, Anna Zanetti¹⁷, Greta Carrara¹⁸, Carlo Alberto Scirè¹⁹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Azienda Ospedaliera San Camillo of Rome, Roma, Italy, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Reumatologia, Università e Policlinico di Bari, Bari, Italy, ⁶UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁷Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy, ⁸Rheumatology Unit, University of Pisa, Pisa, Italy, ⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ¹⁰Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹¹Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, ¹²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ¹³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁴Dipartimento di Medicina Interna e Specialita` Mediche, Sapienza Universita` di Roma, Roma, Italy, ¹⁵Rheumatology, University Hospital of Siena, Siena, Italy, ¹⁶UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ¹⁷Italian Society for Rheumatology, Milano, Italy, ¹⁸Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ¹⁹Italian Society for Rheumatology, Milan, Italy
Background/Purpose:Preventing organ damage is a major challenge in Systemic Lupus Erythematosus (SLE).To evaluate factors associated with development of steroid-related and unrelated damage in an inception…
Abstract Number: 2604 • 2017 ACR/ARHP Annual Meeting
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Ronald F van Vollenhoven¹, April Thompson², Bonnie Pobiner², Joe Eastman², Anne Hammer², James Groark³ and Damon Bass³, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK Collegeville, Collegeville, PA
Background/Purpose: Reduced corticosteroid use is considered a key goal in SLE treatment. This concept of ‘steroid-sparing’, seen with intravenous (IV) belimumab based on cumulative steroid…
Abstract Number: 2913 • 2015 ACR/ARHP Annual Meeting
Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation
Dario Roccatello¹, Savino Sciascia², Daniela Rossi¹, Carla Naretto³, Simone Baldovino³, Mirella Alpa³, Ilaria Salussola³ and Vittorio Modena³, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³CMID, Torino, Italy
Background/Purpose: B-lymphocytes (BL) play a critical role in Systemic Lupus Erythematosus (SLE). BL depletion therapy still remains an attractive option, despite the disappointing results of…
Abstract Number: 2896 • 2013 ACR/ARHP Annual Meeting
Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce¹, Aidan O'Keefe², Li Su³, Vernon Farewell⁴, John G. Hanly⁵, Susan Manzi⁶, Murray B. Urowitz⁷ and Systemic Lupus International Collaborating Clinics (SLICC)⁸, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Cambridge, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁵Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Irreversible damage is an important outcome in patients with SLE. We aimed to study damage accrual in early SLE. We examined the rate of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].